SCHEMBL7617889

SCHEMBL7617889

CN1CCC=C(c2nsnc2SCCCC(OC(=O)C(=O)OC(CCCSc2nsnc2C2=CCCN(C)C2)Sc2nsnc2-c2cccnc2)Sc2nsnc2-c2cccnc2)C1

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 11/20 0.55
CHRM4 P08173 3/20 0.54
SIGMAR1 Q99720 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL7617887 0.86 CHRM1 (0.66) CHRM1CHRM4
SCHEMBL7613097 0.86 CHRM1 (0.74) CHRM1CHRM4SIGMAR1
SCHEMBL7614562 0.83 CHRM1 (0.58) CHRM1CHRM4SIGMAR1
SCHEMBL7610832 0.80 CHRM1 (0.60) CHRM1CHRM4
SCHEMBL7620935 0.80 CHRM1 (0.59) CHRM1CHRM4SIGMAR1
SCHEMBL7614590 0.80 CHRM1 (0.60) CHRM1CHRM4
SCHEMBL7617535 0.79 CHRM1 (0.58) CHRM1CHRM4SIGMAR1
SCHEMBL7618376 0.79 CHRM1 (0.53) CHRM1CHRM4
SCHEMBL7617184 0.77 CHRM1 (0.55) CHRM1CHRM4
SCHEMBL7609540 0.77 CHRM1 (0.60) CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP disclosed
US-RE36375-E Treatment of Alzheimer's disease using azacyclic compounds NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
US-5773452-A ALZHEIMER'S DISEASE; COGNITION ACTIVATORS NOVO NORDISK ALS (DK) 1998-06-30 US disclosed
US-RE35822-E COGNITION ACTIVATORS NOVO NORDISK A/S (DK) 1998-06-09 US disclosed
US-5750541-A 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION NOVO NORDISK A/S (DK) 1998-05-12 US disclosed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US disclosed
US-5658932-A AZACYCLIC COMPOUNDS; COGNITIVE FUNCTION STIMULANTS; ALZHEIMER'S DISEASE NOVO NORDISK A/S (DK) 1997-08-19 US disclosed
US-5571826-A 1,2,5-THIADIAZOLE OR 1,2,5-OXADIAZOLE AS ANALGESICS NOVO NORDISK A/S (DK) 1996-11-05 US disclosed
US-5565475-A Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives MUHLHAUSER MARK A (US) 1996-10-15 US disclosed
US-5559136-A Treatment of Alzheimer's disease using azacyclic compounds NOVO NORDISK A/S (DK) 1996-09-24 US disclosed
US-5545638-A USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND NOVO NORDISK A/S (DK) 1996-08-13 US disclosed
US-5376668-A Cholinergic agents as cognition activators in treatment of Alzheimer*s disease NOVO NORDISK A/S (DK) 1994-12-27 US disclosed